ALBO News and Press, Albireo Pharma Inc. From 11/02/22

– BOLD is the first, largest, and only global Phase 3 trial designed to meet regulatory agencies' requirements – On track to report topline data by the end of 2024, reinforcing Bylvay's expected position as first IBAT inhibitor to market in biliary atresia...

– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS) – Oral late breaker provides evidence of disease modification in PFIC – Analysis of PEDFIC 1 data showed restoration of bile acid secretion in patient...

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on November 8, 2022, to provide a b...

– New data presented at the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition meeting (NASPGHAN) – Earlier treatment with Bylvay (odevixibat) provided greater efficacy in children with PFIC – Direct link between level ...

Summary Sales for Bylvay's first approved indication is increasing. The company recently posted superb data for an orphan disease known as Alagille Syndrome. There is also another label expansion of Bylvay for biliary atresia that is likely to bear fruits. Al...

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference on October 1...

Top-line data for a phase 3 trial of Albireo Pharma's ( NASDAQ: ALBO ) Bylvay (odevixibat) in Alagille syndrome showed the candidate met its primary endpoint of significant improvement in pruritus . Shares are up 17% in premarket trading. It also met a...

Highly statistically significant improvement in pruritus primary endpoint (p=0.002) Significant reductions in key secondary endpoint of serum bile acid levels (p=0.001) Substantial improvements in multiple sleep parameters Well tolerated with low incidence of d...

– Seven abstracts accepted, including one oral presentation highlighting long-term data demonstrating Bylvay ® (odevixibat) durable efficacy in patients with all types of PFIC – One abstract describes data on A3907, a systemic ASBT inhibitor, in deve...

Summary Albireo Pharma, Inc. is expanding its Bylvay label for two other rare liver conditions, biliary atresia and Alagille syndrome. The company is poised to report topline data for the Phase 3 (ASSERT) trial for Alagille syndrome this Fall. Meanwhile, the firm inked a lucra...